Robert Owen Dillman
Affiliation: Hoag Cancer Center
- Dillman R, Duma C, Ellis R, Cornforth A, Schiltz P, Sharp S, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009;32:914-9 pubmed publisher..Intralesional LAK cell therapy is safe and the survival sufficiently encouraging to warrant further evaluation in a randomized phase 2 trial of intralesional therapies with LAK or carmustine-impregnated wafers. ..
- Dillman R, Duma C, Schiltz P, DePriest C, Ellis R, Okamoto K, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27:398-404 pubmed..The median survival rates are higher than reported in most published series of patients who underwent reoperation for recurrent GBM. A randomized trial would be needed to establish therapeutic benefit...